Bharat Biotech’s Nasal Vaccine iNCOVACC To Cost Rs 800: Sources
The iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein.
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
[vc_row][vc_column]
[/vc_column][/vc_row]Browsing Tag
Bharat Biotech
Bharat Biotech’s Covaxin Safe For Children Aged 2-18: Study
New Delhi: Bharat Biotech, which has a stockpile of more than 50 million doses of Covaxin ready to be distributed as required, is well-tolerated and immunogenic in the paediatric population in phase 2/3 studies, according to a study…
Covaxin Closer To Emergency Use Nod By WHO
Hyderabad: The World Health Organization (WHO) is a step closer to granting an emergency use listing (EUL) to Covaxin after Bharat Biotech provided additional data on the vaccine sought by the world body.
According to a document on the WHO…
Covaxin’s Supply Price To Govt Not Sustainable: Bharat Biotech
New Delhi: The supply price of COVID-19 vaccine Covaxin to the Central government at Rs 150 per dose is not sustainable in the long run, Bharat Biotech said on Tuesday.
The Centre’s supplying price is pushing the pricing structure for the…
Vaccine Update: Covaxin Trials On Children Start In India
Patna: Bharat Biotech has started paediatric trials of its COVID-19 vaccine Covaxin at the All India Institute of Medical Sciences (AIIMS) Patna.
The Drugs Controller General of India last month approved clinical trials of Covaxin among…
PIL Against Covaxin Trial On 2-18 Age Group In Delhi High Court
New Delhi: The Delhi High Court on Wednesday heard a PIL, to set aside the permission granted by the Drugs Controller General of India to Bharat Biotech for conducting the phase II/III clinical trial of its Covaxin COVID-19 vaccine on the…
Govt Approves Rs 3,000 Crore Credit To Serum Institute & Rs 1,500 Crore To Bharat Biotech For…
New Delhi: COVID-19 vaccine manufacturers Bharat Biotech and Serum Institute of India (SII) will get Rs 1,500 crore and Rs 3,000 crore each as supply credit from the Finance Ministry.
The Ministry, which gave an in-principle nod for the…
Covaxin Effective Against UK Strain Of Coronavirus: Study
New Delhi: Bharat Biotech's Covaxin is effective against the UK variant of the virus. Taking to Twitter, Bharat Biotech said "Covaxin effectively neutralises UK variants of SARS-CoV-2 reducing the possibility of mutant virus escape". The…
Bharat Biotech’s Covaxin Found To Be Safe, Induced Immune Response In Phase-1: Data
New Delhi: Bharat Biotech's coronavirus vaccine Covaxin has been found to be well-tolerated and produced an immune response, says the Phase-1 interim data published by the company in the peer-reviewed British medical journal Lancet,…
Centre Issues Letter Of Comfort To Bharat Biotech For 45 Lakh Doses Of Covaxin
New Delhi: Bharat Biotech has secured a fresh Letter of Comfort from the Centre for another 45 lakh doses of its COVID-19 vaccine Covaxin. Out of this, it will supply over eight lakh doses to countries such as Mauritius, Philippines and…